MEDICALSYSTEM(SZ:300439)2026-01-30 09:30Financial Performance - The estimated net profit for 2025 is projected to be between ¥56 million and ¥73 million, representing a decline of over 50% compared to the previous year[3]. - The net profit attributable to shareholders is expected to decrease by 78.29% to 71.71%, down from ¥257.9972 million in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is anticipated to be between ¥18 million and ¥27 million, reflecting a decline of 91.83% to 87.75% from ¥220.4061 million last year[3]. - The estimated impact of non-recurring gains and losses on net profit attributable to shareholders is approximately ¥42 million[6]. Business Expansion and Strategy - The company has achieved a record of 14 Class II medical device registrations for its mass spectrometry platform in 2025, expanding its application scope[6]. - The company has successfully expanded its precision lipid testing project to three additional provinces, now covering a total of seven provinces[6]. - The company is actively implementing an "outbound" strategy, with initial success in market expansion in Russia, the Middle East, and Southeast Asia, leading to steady growth in international business revenue[6]. - In 2026, the company plans to enhance cost management, increase market share in the immunology field, and accelerate the layout of precision diagnostics and international business[7]. Profit Margin Challenges - The decline in profit is attributed to policy impacts on the in vitro diagnostics industry, leading to revenue decreases in high-margin self-produced business segments[6]. - Fixed asset depreciation expenses have increased due to the solidification of the life and health industry park project, further compressing profit margins[6].